Prophylactic Conjoint Tendon Lengthening During Reverse Shoulder Arthroplasty to Reduce Anterior Shoulder Pain at One Year

What this Trial Is About

This research aims to evaluate whether prophylactic conjoint tendon lengthening (CTL) during reverse shoulder arthroplasty (RSA) can prevent or reduce anterior shoulder pain one year after surgery. RSA is a surgical treatment for severe shoulder arthritis with rotator cuff damage that reverses the ball and socket of the shoulder joint to improve function and pain. Some patients experience persistent front shoulder pain after RSA, possibly due to increased tension on the conjoint tendon, and this study will investigate if CTL can address this issue. Participants will be randomly assigned to one of two groups: one receiving standard RSA and the other receiving RSA combined with CTL, where the conjoint tendon is incised and lengthened during surgery to reduce tension. The study will compare outcomes at 6 and 12 months after surgery between these groups, assessing pain intensity, shoulder motion, strength, activity levels, and patient-reported results. The trial will also explore factors that may predict how well patients respond to CTL. During the study, participants will undergo regular assessments including the American Society of Shoulder and Elbow Surgeons (ASES) score at 12 months as the primary outcome. Secondary measures include the Visual Analog Scale (VAS) for pain and the Shoulder Pain and Disability Index (SPADI). Participants will be monitored through these evaluations to understand the impact of the surgical procedures on their shoulder pain and function over the course of one year.

Prophylactic Conjoint Tendon Lengthening During Reverse Shoulder Arthroplasty Outcomes